Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation.
about
Biologics in organ transplantationImpact of maintenance immunosuppressive regimens--balance between graft protective suppression of immune functions and a near physiological immune response.Kidney transplant survival in pediatric and young adultsAssociation of HLA mismatch with death with a functioning graft after kidney transplantation: a collaborative transplant study report.Belatacept : a new biological agent for maintenance immunosuppression in kidney transplantation.Steroids in kidney transplant patientsCyclosporine versus tacrolimus: cost-effectiveness analysis for renal transplantation in Brazil.Comparison of azathioprine with mycophenolate mofetil in a living donor kidney transplant programmeThe second report of the Nordic Pediatric Renal Transplantation Registry 1997-2012: More infant recipients and improved graft survivals.Comparative pharmacokinetic study of two mycophenolate mofetil formulations in stable kidney transplant recipients.Induction Therapy for Kidney Transplant Recipients: Do We Still Need Anti-IL2 Receptor Monoclonal Antibodies?Cost-effective immunosuppressive options for solid organ transplantation: a guide to lower cost for the renal transplant recipient in the USA.Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation.Current immunosuppressive treatment after kidney transplantation.An evaluation of sirolimus in renal transplantation.Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update.The safety of calcineurin inhibitors for kidney-transplant patients.New formulations of tacrolimus and prevention of acute and chronic rejections in adult kidney-transplant recipients.Renal transplant immunology in the last 20 years: A revolution towards graft and patient survival improvement.Polyomavirus Reactivation and Immune Responses to Kidney-Specific Self-Antigens in Transplantation.Experience with belatacept rescue therapy in kidney transplant recipients.Heterogeneity of induction therapy in Spain: changing patterns according to year, centre, indications and resultsCRTC2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation.The predictive value of kidney allograft baseline biopsies for long-term graft survival.Cyclosporine versus tacrolimus in immunosuppressive maintenance regimens in renal transplants in Brazil: survival analysis from 2000 to 2004.Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.Treatment of ureteral complications after kidney transplantation with native ureteropyelostomy reduces the risk of pyelonephritis.Malignancies in transplanted patients: Multidisciplinary evaluation and switch to mTOR inhibitors after kidney transplantation - experiences from a prospective, clinical, observational study.Lymphotoxin expression in human and murine renal allografts.Ten-year kidney transplant survival of cyclosporine- or tacrolimus-treated patients in Brazil.Safety profile comparing azathioprine and mycophenolate in kidney transplant recipients receiving tacrolimus and corticosteroids.Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.Long-term outcome of belatacept therapy in de novo kidney transplant recipients - a case-match analysis
P2860
Q26829578-AD6BCA34-9352-47BC-9191-64AB9A669F79Q33845320-10547F2E-E06A-4457-8942-C7ED0D5611C4Q34044051-9AF106C9-B724-428D-B3C3-DD18C4368C6EQ34294557-00259A05-A5E0-4579-BB89-EC963EFD2D90Q34638056-A2D84DD0-F52E-4856-9294-E999ECEFC71CQ34862560-9EBD4196-CCF0-4810-8E1D-A4D5C5BCBFC2Q35281597-81D943F1-F956-4443-9A5D-1E01F444C316Q35351287-93B0DCD0-4BE2-4423-8A7A-A4989AEE3316Q35917798-2906A0EC-B419-4F75-B65E-9A2108B88CBEQ36482172-8CEC7E35-2FEC-47C3-9E93-DD129E6C1766Q37561282-70889CE8-9F0E-49A8-9CA5-D91803226331Q37810962-497E87BD-BDF0-4C77-B948-AF76140A9BCAQ37818197-613B8F82-1367-47A2-981F-5B2A3E98A2CBQ37834028-059CBCE3-6BF1-4C64-831A-1999D2DE86EDQ38038696-B920A250-BF15-40B7-B9B4-EB0BF3310E0EQ38208983-02D23A3F-B2B1-481A-A116-C04F70655EEFQ38578386-96115BFF-3686-4DF7-A514-80AB4B988BD2Q38791651-76B420F1-C4E4-4F1E-AF36-618DF0E77499Q38967258-DFA9B4AD-988E-4D1B-9409-157BC59DA907Q39207543-1B928BFB-9DFC-459D-B5DE-04737E7CDF42Q40513558-48861E1F-236C-4C06-8D6C-9AA618A1E36AQ40704973-A5417B80-AACB-44E6-AD43-820B428EA6CDQ40880029-A4743B27-3678-4CA1-9611-C36D666CABE9Q41828910-41F7EF5E-A3CD-4A8F-8163-13797AA3742EQ43222628-43A4D148-7CD5-45BE-BE2F-554C316523B7Q46007205-D480E7C8-2F28-403A-A5A1-051B9AD403A2Q46034018-4B6CAC85-E4AA-46D7-A647-09FF09E3D8E1Q47901311-25DDFD49-FBCE-4C58-925F-49DFF6DE5631Q48309886-756AC139-F437-4314-BACF-2740E15DD493Q50211007-38B751A9-3C63-49A2-8469-EA16ACC78BECQ51873726-138988BB-8CF5-456D-89C8-2E7757EFADA0Q54505605-27B0AD14-2B17-4B22-ABE1-D2853A8F0729Q57305845-555A3A32-B4F8-4723-8377-344839EBED78
P2860
Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Influence of immunosuppressive ...... after kidney transplantation.
@en
Influence of immunosuppressive ...... after kidney transplantation.
@nl
type
label
Influence of immunosuppressive ...... after kidney transplantation.
@en
Influence of immunosuppressive ...... after kidney transplantation.
@nl
prefLabel
Influence of immunosuppressive ...... after kidney transplantation.
@en
Influence of immunosuppressive ...... after kidney transplantation.
@nl
P1433
P1476
Influence of immunosuppressive ...... after kidney transplantation.
@en
P2093
Bernd Döhler
Collaborative Transplant Study
P304
P356
10.1097/TP.0B013E318199C1C7
P577
2009-03-01T00:00:00Z